• Aliases: AP23573, MK-8669, deforolimus
    • Orally bioavailable mTOR inhibitor
    • Phase 3 clinical trials with soft tissue and bone sarcoma (SUCCEED) improved PFS, but did not result in FDA approval
    • Currently under investigation in clinical trials for breast cancer (phase 2), endometrial and ovarian cancer, renal cell carcinoma, and other tumors solids (phase 1)
    • Recommended dose: 40 mg q.i.d. × 5 days/week
    • Half-life: 42 hours
    • Common side effects: Stomatitis, fatigue, mucosal inflammation, rash, mouth ulceration, anemia, diarrhea, thrombocytopenia
    (Mita et al., 2013)
    Other topics in Targeted and Immunotherapy Agents